DTx Pharma, Inc., a San Diego, CA-based biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, completed a $100m Series B financing.
The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital and existing investors Friedman Bioventure Fund, Eli Lilly and Company, Viva BioInnovator (Viva Biotech Holdings, 1873.HK), and ExSight Ventures. In connection with this financing, Matthew Hammond, Ph.D., Principal at RA Capital Management, and Dan Becker, M.D., Ph.D., Partner at Access Biotechnology, will join DTx Pharma’s board of directors.
The company intends to use the funds to utilize its FALCON fatty acid motifs to advance assets into clinical development across several therapeutic areas over the next few years.
Led by Arthur T. Suckow, Ph.D., chief executive officer, and Denise Bevers, chief operating officer, DTx Pharma is a biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease. The company’s proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types.